1. Which of the following malignancies are associated with increased risk of tumor lysis syndrome (TLS)?
2. Which of the following is NOT a factor in stratifying TLS risk in patients receiving anticancer therapy?
3. Rapid breakdown of malignant cells due to effective anticancer therapy may lead to TLS.
4. Efficacy and safety of ELITEK® (rasburicase) were studied in:
5. What was the incidence of hypersensitivity reactions in patients treated with ELITEK?